A drug safety alert urging vigilance among healthcare professionals and patients concerning the painkiller Meftal has been recently issued by the Indian Pharmacopoeia Commission (IPC). Meftal, commonly prescribed for menstrual cramps and rheumatoid arthritis, contains mefenamic acid and is used to treat various conditions, including inflammation, fever, and dental pain.
The commission’s alert, issued on November 30, highlighted a preliminary analysis from the Pharmacovigilance Programme of India (PvPI) database. This analysis revealed instances of drug reactions leading to eosinophilia and systemic symptoms (DRESS) syndrome associated with the use of Meftal.
Also Read: Kamleshwar Dodiya: MLA From Slum Says He Would Teach Chouhan His Job
The alert advises healthcare professionals and patients to closely monitor the potential adverse drug reactions (ADRs) linked to the use of Meftal. In the event of such reactions, individuals are encouraged to report the matter to the national coordination centre of the PvPI under the commission. Reporting can be done by filling out a form on the website www.ipc.gov.in, through the android mobile app ADR PvPI, or by contacting the PvPI Helpline No. 1800-180-3024.
As an autonomous institution of the Ministry of Health, the IPC sets standards for all drugs manufactured, sold, and consumed in India, ensuring drug safety and quality.
Also Read: Assault, Threat, Rape, ARRESTED! The ‘Supreme Clean’ MLA From Slum Has 12 Record Cases